Landscapes / Companies
Tanabe Pharma America, Inc. not checked
FollowEvery new trial, moved date and filing, and a Monday email
Drugs
2
in active trials · 6 in all
Trials
2 active
20 since 2021
Drugs2
| Drug | How it works | Partner | Stage
Sources: FDA: the drug development process, ClinicalTrials.gov glossary | Next date
| Details |
|---|---|---|---|---|---|
— |
Phase 3 | Dec 2027Phase 3 trial completes | |||
| Next date | Dec 2027 · Phase 3 trial completes | ||||
| Also tested for | EPP, XLP | ||||
| Open drug page | |||||
— |
Phase 1/2 | Aug 2028Phase 1/2 trial completes | |||
| Next date | Aug 2028 · Phase 1/2 trial completes | ||||
| Also tested for | Head and Neck Squamous Cell Carcinoma (HNSCC), Non-small Cell Lung Cancer (NSCLC) and 14 more | ||||
| Open drug page | |||||
About
- No active trial
- Elismetrep, MT-2990, MT-3921, MT-6345
- SEC filings
- None: it does not file with the US SEC
- Sources
- ClinicalTrials.gov updated 18 Nov 2026 Industry-sponsored drug trials since 2021